BioPharma Global

Bluebird Bio gene therapy wins first FDA approval for rare blood disorder

Read more: https://www.biopharmaglobal.com/2022/08/26/bluebird-bio-gene-therapy-wins-first-fda-approval-for-rare-blood-disorder/

Bluebird Bio gene therapy wins first FDA approval for rare blood disorder SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designa...

Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

Read more: https://www.biopharmaglobal.com/2022/08/24/attralus-receives-u-s-fda-orphan-drug-designation-for-at-01-iodine-i-124-evuzamitide-an-investigational-diagnostic-for-the-management-of-transthyretin-amyloidosis/

Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designa...

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma

Read more: https://www.biopharmaglobal.com/2022/08/22/alx-oncologys-evorpacept-receives-fast-track-designation-from-fda-as-first-line-treatment-for-head-and-neck-squamous-cell-carcinoma/

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) ...

Follow us on Instagram: https://www.instagram.com/biopharmaglobal/